Clinical Trial Update: Nebulised Rt-PA for ARDS Due to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nebulised rt-PA for acute respiratory distress syndrome caused by COVID-19 has completed and results have been posted (2025-08-11).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• alteplase (nebulised rt-PA) (alteplase)

Snippet

Sponsor: University College, London | Conditions: COVID | Phase 2 | Status: COMPLETED | Results posted: 2025-08-11